Daniel Janney Net Worth

The estimated Net Worth of Daniel Janney is at least $46.8 Milion dollars as of 8 June 2023. Mr. Janney owns over 50,000 units of Allakos Inc stock worth over $65,491 and over the last 21 years he sold ALLK stock worth over $46,303,733. In addition, he makes $463,260 as Independent Chair of the Board at Allakos Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Janney ALLK stock SEC Form 4 insiders trading

Daniel has made over 18 trades of the Allakos Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of ALLK stock worth $6,418,000 on 8 June 2023.

The largest trade he's ever made was buying 500,000 units of Allakos Inc stock on 17 March 2017 worth over $2,000,000. On average, Daniel trades about 47,467 units every 59 days since 2004. As of 8 June 2023 he still owns at least 107,362 units of Allakos Inc stock.

You can see the complete history of Mr. Janney stock trades at the bottom of the page.

Daniel Janney biography

Daniel S. Janney serves as Independent Chair of the Board of the Company. Mr. Janney is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996, Mr. Janney was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a number of companies including Esperion Therapeutics, Krystal Biotech, Lassen Therapeutics and Prolacta Bioscience. Mr. Janney is currently a member of the executive committee of the California Academy of Sciences Board of Trustees. He holds a Bachelor of Arts in history from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

What is the salary of Daniel Janney?

As the Independent Chair of the Board of Allakos Inc, the total compensation of Daniel Janney at Allakos Inc is $463,260. There are 9 executives at Allakos Inc getting paid more, with Robert Alexander having the highest compensation of $12,559,300.

What's Daniel Janney's mailing address?

Daniel's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.

Insiders trading at Allakos Inc

Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red... a Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.

What does Allakos Inc do?

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

Complete history of Mr. Janney stock trades at Dynavax Technologies, Esperion Therapeutics, Viveve Medical Inc, Krystal Biotech Inc, Allakos Inc a Sutro Biopharma Inc

Allakos Inc executives and stock owners

Allakos Inc executives and other stock owners filed with the SEC include:

• Robert Alexander,
  Chief Executive Officer, Director
• Adam Tomasi,
  President, Chief Operating Officer
• Henrik Rasmussen,
  Chief Medical Officer
• Leo Redmond,
  Chief Financial Officer
• Mark Asbury,
  Chief Legal Officer and General Counsel
• Dr. Robert Alexander Ph.D.,
  CEO & Director
• Dr. Adam L. Tomasi Ph.D.,
  Pres & COO
• Dr. Henrik Sandvad Rasmussen,
  Strategic Advisor
• Mark Asbury,
  Chief Legal Officer & Gen. Counsel
• Daniel Janney,
  Independent Chair of the Board
• Robert Andreatta,
  Independent Director
• John McKearn,
  Independent Director
• Paul Walker,
  Independent Director
• Steven James,
  Independent Director
• Dr. Craig Paterson M.D.,
  Chief Medical Officer
• Alan Chang,
  Director of Medical Affairs & Data Analytics
• Tim Varacek,
  Chief Commercial Officer
• Dr. Sally D. Bolmer,
  Sr. VP of Regulatory Affairs & Drug Devel.
• Dr. Ruby Casareno Ph.D.,
  Sr. VP of Technical Operations
• Baird Radford III,
  Chief Financial Officer
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Iii, L.P.River...,
  
• Partners Viii, L.P.Alta Par...,
  
• Neil Murray Hamilton Graham,
  
• Amy L Ladd,
  
• Dolca Thomas,
  
• Partners Next Gen Fund I Ma...,
  
• Peter A Hudson,
  
• Robert J More,
  
• Guy P Nohra,
  10% owner
• Natalie C. Holles,
  Director
• Partners Next Gen Fund I Ma...,
  
• Margaret Nell Fitzgerald,
  General Counsel and Secretary
• Craig A. Paterson,
  Chief Medical Officer
• Everett Rand Sutherland,
  Director
• Partners Management Viii, L...,
  
• Chin Hyok Lee,
  Chief Medical Officer
• Harlan Baird Radford,
  Chief Financial Officer